Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAK-850
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TAK-850 is a quadrivalent influenza vaccine candidate that was developed by Takeda for the prevention of infections caused by influenza virus subtypes A and B. It was designed to be administered as a single subcutaneous injection and evaluated in clinical trials for its safety and immunogenicity compared to standard influenza hemagglutinin (HA) vaccines. The development of TAK-850 has been discontinued[1][2][3][4].
02
Targets
BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on TAK-850.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAK-850.